The Predictive Capacity of Machine Learning Models for Progressive Kidney Disease in Individuals With Sickle Cell Anemia

Description

This is a multicenter prospective, longitudinal cohort study which will evaluate the predictive capacity of machine learning (ML) models for progression of CKD in eligible patients for a minimum of 12 months and potentially for up to 4 years.

Conditions

Sickle Cell Disease, Kidney Diseases, Chronic

Talk to us

Study Overview

On this page

Study Details

Study overview

This is a multicenter prospective, longitudinal cohort study which will evaluate the predictive capacity of machine learning (ML) models for progression of CKD in eligible patients for a minimum of 12 months and potentially for up to 4 years.

Predicting Progression of Chronic Kidney Disease in Sickle Cell Anemia Using Machine Learning Models [PREMIER]

The Predictive Capacity of Machine Learning Models for Progressive Kidney Disease in Individuals With Sickle Cell Anemia

Condition
Sickle Cell Disease
Intervention / Treatment

-

Contacts and Locations

Chicago

University of Illinois at Chicago, Chicago, Illinois, United States, 60612

Winston-Salem

Wake Forest University, Winston-Salem, North Carolina, United States, 27109

Memphis

The University of Tennessee Health Science Center, Memphis, Tennessee, United States, 38104

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

For general information about clinical research, read Learn About Studies.

Eligibility Criteria

  • 1. HbSS or HbSβ0 thalassemia, 18 - 65 years old;
  • 2. non-crisis, "steady state" with no acute pain episodes requiring medical contact in preceding 4 weeks;
  • 3. ability to understand the study requirements.
  • 1. pregnant at enrollment;
  • 2. poorly controlled hypertension;
  • 3. long-standing diabetes with suspicion for diabetic nephropathy;
  • 4. connective tissue disease such as systemic lupus erythematosus (SLE);
  • 5. polycystic kidney disease or glomerular disease unrelated to SCD;
  • 6. stem cell transplantation;
  • 7. untreated human immunodeficiency virus (HIV), hepatitis B or C infection; h) history of cancer in last 5 years; i) End-stage renal disease (ESRD) on chronic dialysis; j) prior kidney transplantation.

Ages Eligible for Study

18 Years to 65 Years

Sexes Eligible for Study

ALL

Accepts Healthy Volunteers

No

Collaborators and Investigators

University of Tennessee,

Kenneth I Ataga, MD, PRINCIPAL_INVESTIGATOR, The University of Tennessee Health Science Center

Study Record Dates

2026-01-31